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Abstract  
Background Oxidative stress may be involved in the aetiology of inflammatory disease (IBD) 
and whether dietary polyphenols, which possess antioxidants properties, prevent its 
development is unknown.  
Methods A total of 401,326 men and women age 20-80 years from 8 countries were recruited 
between 1991 and 1998, and at baseline completed validated food frequency questionnaires. 
Dietary polyphenol intake was measured using Phenol-Explorer, a database with information 
on the content of 502 polyphenols.   Incident cases of Crohn’s diseases (CD) and ulcerative 
colitis (UC) were identified during the follow-up period of up to December, 2010. A nested 
case-control study using conditional logistic regression estimated the odds ratios (ORs), and 
95% confidence intervals (CI), for polyphenol intake (categories based on quartiles) and 
developing CD or UC.  
Results In total 110 CD (73% women) and 244 UC (57% women) cases were identified and 
matched to 440 and 976 controls, respectively.  Total polyphenol intake was not associated with 
CD (P trend=0.17) or UC (P trend=0.16). For flavones and CD, there were reduced odds for all 
quartiles, which was statistically significant for the third (OR3th vs 1st quartile =0.33, 95% CI: 0.15, 
0.69) and there was an inverse trend across quartiles (P=0.03). Similarly, for resveratrol, there 
was an inverse association with CD (OR4th vs 1st quartile =0.40, 95% CI: 0.20, 0.82) with an inverse 
trend across quartiles (P=0.02). No significant associations between subtypes of polyphenols 
and UC were found. Effect modification by smoking in CD was documented with borderline 
statistical significance.  
 
Conclusion The data supports a potential role of flavones and resveratrol in CD; future 
aetiological studies should investigate these dietary components and further examine the 
potential for residual confounding. 
 
Key words Polyphenols, Crohn’s diseases, ulcerative colitis, anti-oxidants. 
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Introduction 
The incidence of inflammatory bowel disease (IBD) namely ulcerative colitis (UC) and Crohn’s 
disease (CD) is rising, particularly in westernized nations (1). IBD is an important clinical 
problem, as patients have to take medications life-long, may require surgery and can develop 
serious complications, such as colorectal cancer (2,3). The aetiology of IBD has yet to be 
elucidated, although probably involves an abnormal immunological response to gastrointestinal 
luminal antigens in a genetically susceptible host (2). Documented risk factors include a positive 
family history (3), smoking (4, 5) and dietary components including intake of n-3 and n-6 fatty 
acids (6-8). 
  
There are plausible biological mechanisms for how dietary polyphenols may prevent several 
gastrointestinal diseases, including IBD (9). These bioactive compounds form a large group of 
related organic molecules in plants, and are most abundant in: fruits, some vegetables, tea, 
coffee, cocoa, wine, herbs and spices (10-12). Plant polyphenols are sub-classified according to 
the number of phenol rings in their chemical structure. The largest class is flavonoids which is 
further sub-divided into flavonols, flavones, isoflavones, flavanones, anthocyanidins, and 
flavanols. Other major polyphenol classes are the stilbenes (resveratrol), phenolic acids 
(including hydroxybenzoic acids and hydroxycinnamic acids), and lignans. The subclasses of 
polyphenols vary in different foods e.g. flavonols are widely present in berries, apples and red 
onions; flavanols are mainly found in tea, cocoa and chocolate; isoflavones are commonly 
available in soybeans; lignans are abundant in flaxseed and sesame seed; resveratrol is affluent 
in grapes and wine; flavones are contained mainly in thyme, rosemary and oregano.  
 
A potential mechanism for how polyphenols may prevent IBD is through inhibiting the 
biological process of oxidative stress, and the associated damage to DNA, lipids and proteins. 
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The gastrointestinal mucosa is constantly exposed to luminal pro-oxidants in foods such as 
alcohol, cholesterol oxides and fatty acids. Polyphenol compounds ameliorate oxidative stress 
by acting as free radical scavengers and inducing cellular antioxidant defence modulating 
proteins and genes expression (13, 14). Furthermore, experimental evidence suggests that 
polyphenols may attenuate intestinal inflammation by reducing the expression of pro-
inflammatory proteins through influencing mitogen-activated protein kinases (MAPKs) and the 
transcription factor nuclear factor kB (NF-kB) signalling pathways (15).  
 
The molecular mechanisms for how polyphenols may prevent IBD need to be supported by 
population-based epidemiological studies, demonstrating that initially well people who eat 
lower amounts of polyphenols are more susceptible to developing UC and CD than those eating 
more of these micronutrients. To date, no such epidemiological investigations have investigated 
the polyphenol hypothesis, including prospective studies, the most robust observational study 
design in nutritional epidemiology. The aim of this aetiological investigation was to conduct 
the first such prospective cohort study investigating if dietary polyphenols are inversely 
associated with the development of IBD in participants enrolled into the European Prospective 
Investigation into Cancer and Nutrition Study (EPIC). Demonstrating associations would 
support encouraging higher dietary intakes of polyphenols to reduce the incidence of IBD, and 
possibly their assessment in randomised controlled trials as treatments in patients to improve 
clinical outcomes.  
 
Methods 
Study population 
The methodology of the main EPIC study has been previously described (16); in brief, 520,000 
men and women were recruited in 23 collaborating centres in 10 European countries during the 
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years 1991-1998.  EPIC was originally designed to investigate habitual diet and the aetiology 
of common cancers in the general population. The EPIC-IBD study is a sub cohort of 401,326 
initially healthy men and women without CD or UC at recruitment (supplementary table 1). The 
age of participants at recruitment ranged between 20 to 80 years in the 12 centres from 8 
European countries namely: Denmark, Germany, Greece, France, Italy, the Netherlands, 
Sweden and the United Kingdom. At recruitment lifestyle factors were measured including 
habitual diet using country-specific food frequency questionnaires (FFQs) that included 
information on: smoking, alcohol intake and physical activity. The FFQs listed approximately 
200 different foods and up to nine frequency of intake categories. From these FFQs, dietary 
polyphenol intake was assessed using the Phenol-Explorer database, which contains data on the 
content of 502 polyphenol compounds in 452 plant-based foods (17). The effects of cooking 
and food processing on the polyphenol content of foods were accounted for by applying 
polyphenol-specific retention factors from Phenol-Explorer to the relevant foods (17). A 
retention factor describes the loss or gain of a micronutrient during food processing e.g. a value 
of 0.40 means that 40% of the compound has been retained during processing. 
 
In addition to total polyphenol intake, the four main subclasses, namely flavonoids, lignans, 
stilbenes and phenolic acids, were computed from Phenol Explorer. Total polyphenol content 
was calculated as the sum of the contents of the individual compounds expressed in mg/100g 
food fresh weight. All animal foods that contain no or only traces of polyphenols were excluded 
from the database. Total daily energy intake was also derived from the FFQs. 
 
Follow-up and ascertainment of IBD 
After recruitment, the sub-cohort was subsequently monitored until at least May 2004, and in 
some centres until December 2010, to identify incident cases of both CD and UC.  New cases 
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of IBD were detected by several methods depending on the centre, namely local and national 
IBD registries, self-reported follow-up questionnaires, pathology databases and hospital in-
patient records. All the clinical notes of potential cases were reviewed by local physicians to 
confirm the diagnoses. Those participants who developed indeterminate or microscopic colitis, 
or who had prevalent IBD at recruitment (including IBD diagnosed less than 18 months after 
recruitment) were excluded. The latter helped to ensure the nutritional data were more likely to 
represent habitual diet before the development of symptoms and the subsequent diagnosis of 
IBD.   
 
Statistical analysis 
The analysis was a nested case-control design within a prospective cohort study. 
Four controls per case were randomly selected and matched by age at recruitment (± 6 months), 
gender, date of recruitment into the study (± 3 months) and study centre. The controls were 
alive on the date of diagnosis of the matched case to ensure a similar follow-up time. Absolute 
differences in polyphenol intake between cases and controls were compared with either a 
student’s t-test or Wilcoxon-Mann-Whitney test according to the nature of the distributions. 
The intakes of polyphenols were divided into quartiles across the distribution of the cohort. 
Conditional logistic regression calculated the odds ratios (OR) and 95% confidence intervals 
(95% CI) for the dietary intake of total polyphenols and the subtypes:  flavonoids, lignans, 
stilbenes, phenolic acid and the development of CD and UC separately. All of the models were 
analysed by adjusting for total energy intake (continuous variable), dietary fat and protein. The 
latter adjustment did not alter the observed associations and therefore we only kept total energy 
in the final model. The models were adjusted by educational level (none/primary school, 
technical/professional school, secondary school, longer education (including university)) and 
smoking (never, current or former). As cigarettes contain pro-oxidants, effect modification by 
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smoking status (never smokers versus ever smokers) was evaluated. All analyses were 
performed using SAS (The SAS Statistical Package. version 9.3, SAS institute, Gary, NC).  
 
Results 
Overall, 110 incident cases of CD (73% women; mean age at diagnosis = 55.4 
years, standard deviation (SD) 11.1) and 244 incident cases of UC (57% women; mean age at 
diagnosis 57.5 years, SD=10.3) were identified (Table 1). Being an ever smoker was more 
frequent among CD and UC cases than among controls (Table 1). There were no significant 
statistical differences in the median intakes of either total or any of the sub-types of polyphenols 
between cases and controls (total polyphenols and CD = 1091.6 mg/day vs 1164.8 mg/day; for 
UC = 1226.1 mg/day vs 1203.0 mg/day, respectively (Table 1)).   
 In the multivariable analysis for total polyphenol intake and CD, and using the 
first quartile as the reference category, lower odds were found for all higher quartiles, which 
was statistically significant in the third (OR3 vs 1 quartile=0.38, 95% CI: 0.18, 0.79), but with no 
trend across quartiles (P value for trend =0.17) (Table 2). In subgroups of polyphenols, for 
flavones lower odds were documented in all quartiles and was statistically significant in the 
third (OR=0.33, 95% CI: 0.15, 0.69), with an inverse trend across quartiles (P for trend=0.03). 
Similarly, for resveratrol all higher quartiles were associated with lower odds, which was 
statistically significant for the second quartile (OR2 vs 1 quartile =0.47, 95% CI: 0.25, 0.90) and 
highest quartile (OR =0.40, 95% CI: 0.20, 0.82), with an inverse trend across quartiles (P=0.02). 
For most other polyphenol subtypes, there were inverse, but not statistically significant, 
associations with higher quartiles, and no trends across categories. For isoflavones, the third 
quartile was positively associated with the odds of CD (OR3 vs 1 quartile =2.26, 95% CI: 1.13-
4.53), but no trend across categories (P=0.11). For total polyphenol intake and UC, there were 
no statistically significant associations (Table 3). For subtypes of polyphenols, there were no 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 7 
 
associations within quartiles, apart from a higher odds ratio in the third quartile of flavanols 
(OR3 vs 1 quartile =1.71, 95%CI: 1.09, 2.69) and no trends across quartiles.  
 Further stratified analyses were conducted by smoking status since this may 
hypothetically modify the effects of polyphenols. For non-smokers, there were no associations 
with either total or subtypes of polyphenols with CD or UC (supplementary tables 2 & 3); the 
exceptions were an inverse association with the second quartile of lignans and CD (OR2 vs 1 
quartile =0.06, 95% CI=0.01-0.39), and borderline statistical significant trends for UC with 
flavonols (p=0.08) and isoflavones (p=0.07). In ever smokers (former plus current smokers), 
there were borderline significant trends across quartiles for flavanones (P= 0.07), flavones 
(P=0.07) and lignans (P=0.06) for CD (table 4). In ever smokers, total polyphenol intake was 
positively associated with UC (P trend=0.05), although only the third quartile was statistically 
significant (OR3 vs1 quartile =2.00, 95% CI:1.04, 3.85) (table 5). There were positive associations 
between phenolic acids and UC (OR3 vs 1 quartile =2.11, 95% CI:1.06, 4.22; OR4 vs 1 quartile =2.14, 
95% CI:1.03, 4.46; P trend=0.05) due to the contribution of hydroxycinnamic acid (OR3 vs 1 
quartile =2.01, 95% CI:0.99, 4.07; OR4 vs 1 quartile =2.35, 95% CI:1.13, 4.91; P tend=0.04).  
 
Discussion  
We found no associations between total dietary polyphenol intake and the odds of developing 
either CD or UC. However, certain subtypes of polyphenols, namely flavones and resveratrol, 
were associated with lower odds of CD. There was some evidence of effect modification in ever 
smokers with suggestive inverse associations for CD with flavanones, flavones and lignans, but 
no associations in non-smokers for both UC and CD. The plausible biological mechanisms, 
magnitudes of these effect sizes, biological gradients, temporal data collection and adjustment 
for potential confounders suggest that these inverse associations could be protective ones. 
Mechanistically, certain polyphenols may prevent CD through inhibiting oxidative stress (13), 
which in the intestinal tract may contribute to the pathogenesis and progression of IBD (18, 19). 
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Recent data reported a positive correlation between reactive oxygen species (ROS), reactive 
nitrogen species (RNS) and gastrointestinal mucosal inflammation, which was associated with 
increased pro-inflammatory cytokines such as interleukin 6 (IL-6), interleukin-17A (IL-17A) 
and interleukin -23(IL-23) (20).   
 The suggestion of effect modification for certain polyphenols and CD in smokers, 
a process which induces oxidative stress, but not in non-smokers, provides evidence for the role 
of this metabolic process in the aetiology of CD. Oxidative stress develops via mechanisms 
including bacteriologic and immunologic pathways, which may support the varying 
associations of polyphenols with CD and UC; for example, antibiotic treatment for CD but not 
UC, and the distinct immune responses of CD (TH1 cytokine profile) and UC (TH2 profile) 
(the TH1 cytokine profile is involved in immune response to infection but not TH2 profile) 
support a possible role for the gut microbiota in CD (21). Furthermore, specific polyphenols, 
such as stilbenes (particularly resveratrol) may alter the composition of the gut microbial 
ecosystem, as supported by evidence in rats (22). Moreover, patients with active CD, compared 
to active UC, may have higher levels of oxidative stress characterised by higher superoxide 
dismutase (SOD) activity leading to H2O2 production increasing lipid peroxidation, and 
inhibiting mitochondrial function (23). CD patients have higher ONOO− (peroxynitrite) content, 
a by-product of iNOS (the inducible isoform of nitric oxide synthases (NOS)) that is highly 
expressed in activated macrophages and neutrophils of colonic mucosa (24). Finally, 
polyphenols possess not only antioxidant properties but also other bioactive functions including 
vasodilatory, antiviral, antibacterial, anti-inflammatory and anticarcinogenic effects, as well 
modulating signalling pathways influencing inflammation such as phospholipase A2, 
cyclooxygenase, lipoxygenase and the induction of NF-kB and MAPK signalling pathways 
(25).  Most polyphenols were associated with a decreased odds of CD, although the trends were 
only statistically significant for flavones and resveratrol. This may suggest either firstly 
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different polyphenols have varying biological activities in preventing CD, or secondly there 
were insufficient cases to detect significant associations in other groups.  Experimental work to 
elucidate any differential properties of specific polyphenols and how these may influence 
aetiology, plus further cohort follow-up to accrue more cases is required to clarify if there are 
associations. In UC, there was a positive association between hydroxycinnamic acid and UC 
among ever smokers, but not non-smokers, although we are not aware of any biological 
mechanisms to explain this, and we cannot discount the possibility that this is a false positive 
result. Hydroxycinnamic acid is mainly obtained from coffee, and the possibility of residual 
confounding exists, if there is another component of coffee which increases the risk of UC.    
              No previous epidemiological studies, as far as we are aware, have investigated 
polyphenols in the aetiology of either CD or UC. However, other foods that contain these 
micronutrients such as fibre-rich vegetables and fruits, have been studied (12, 26). A meta-
analysis (of 2 cohort studies, and 5 case-control studies) reported that total dietary fibre was  
associated with a decreased risk of CD (pooled OR=0.44 ,95CI: 0.29-0.69), but not UC (pooled 
OR=0.80, 9%%CI: 0.64-1.00) (27). This inverse association for CD with fibre may be due to 
micronutrients in plant-based foods, such as polyphenols. Another meta-analysis of 14 case-
control studies documented that consumption of vegetables was inversely associated with the 
risk of UC, but not CD. However, in a sub-group analysis for vegetables and CD there was a 
significantly inverse association for studies carried out in Europe, but not in Asia (27). The 
inverse association with vegetables in the European population is consistent with our findings 
because some polyphenols e.g. lignans, are abundant in western foods. The increased odds 
associated with some categories of isoflavones in CD might be linked  to other conditions, such 
as lactose intolerance often undiagnosed in IBD sufferers who avoid dairy foods but have 
increased intakes of soybean foods that are rich in isoflavones (28-30).  To help clarify if inverse 
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associations do exist with polyphenols, further observational studies, ideally prospective cohort 
investigations are required. 
 
This observational study has several methodological strengths and limitations. The strengths 
include the prospective cohort design, which minimised both selection bias and recall bias for 
dietary polyphenol intake; and a full and detailed assessment of dietary polyphenol intake was 
derived from interpreting the FFQ using the polyphenol database specifically developed for 
EPIC (17). FFQs do have several limitations compared to 24-hour dietary recall or food diaries, 
in that a set list of certain foods’ portion sizes and frequencies of intake are listed, therefore not 
allowing for any variations in individuals’ specific intakes. Dietary assessments using weighed 
records of intake over a set time are not pragmatic in large scale epidemiological studies. The 
online resource, Phenol-Explore (http://phenol-explorer.eu/) is the first comprehensive database 
on polyphenol content of foods to be used in epidemiological studies. The latest version also 
includes detailed data on the effects of food processing and cooking. A further methodological 
strength was that all the case notes of potential IBD patients were reviewed by physicians to 
confirm the diagnoses to reduce measurement bias.  Follow-up bias should be minimal as the 
number of cases identified was similar to that in a large incidence study conducted in many 
European countries (31). However, more cases in the analyses, particularly according to 
smoking status, would have allowed a better estimate of the precision of effect sizes. Further 
follow-up of the cohort is now being planned, including in centres not in the original EPIC-IBD 
study. Our findings may only be applicable to a middle-aged to elderly patient group with IBD, 
although the peak prevalence of both UC and CD is in younger people. However, the results 
are generalizable in that we studied both male and female participants from 8 countries with 
variation in their dietary habits, and the site of disease in the gastrointestinal tract was similar 
to that expected. Residual confounding may exist, namely there are other variables, possibly 
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dietary or other health-conscious behaviour, associated with polyphenols which are actually the 
true aetiological exposures. Polyphenols are present in several foods including fruits and 
vegetables, and it may be other micronutrients in these food groups that actually influence risk. 
The EPIC-IBD study is continuing to investigate other dietary hypotheses and polyphenols will 
be adjusted for any new dietary variables for which associations are detected. Furthermore, 
participants’ diet may change over time, and as we only had one dietary measure, namely that 
at recruitment, this could introduce measurement error, making any smaller associations 
difficult to detect. However, such measurement error would introduce an under-estimate of 
effect sizes, rather than a spurious over-estimate. Measurement error may be reduced by 
controlling for total energy intake. Relatively small numbers of cases, particularly according to 
smoking status would mean small effect sizes may not be identified and further cohort follow-
up is required to detect such differences. The higher proportions of smoking in UC was 
unexpected and maybe because there was just one measure of smoking, namely at recruitment 
which was several years before diagnosis. This may be relevant if recent cessation of smoking 
before the development of symptoms is important in aetiology. Finally, in this investigation 
multiple comparisons between polyphenols and the odds of IBD were undertaken, which could 
result in false positive results. Although, this is possible, it is less likely as there are plausible 
biological mechanisms for the inverse associations, including the suggestion of effect 
modification in the smoking group, and for several of these micronutrients there were biological 
gradients for the ORs across quartiles.     
 
In conclusion, we have reported higher intakes of some polyphenols, namely flavones and 
resveratrol, are associated with a lower risk of CD, but no associations with polyphenol intake 
for UC. In CD, inverse associations were documented for some sub-groups of polyphenols in 
smokers, but not non-smokers, supporting a role for oxidative stress in the aetiology. Residual 
confounding for other dietary variables associated with polyphenols is a possibility. Further 
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large prospective cohort studies are warranted to measure polyphenol intake and determine if 
the associations are consistent. If so, increasing the dietary intake of these micronutrients may 
help reduce the risk of developing CD, and support their assessment as therapies in patients 
with established disease.  
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Table 1 Characteristics of participants in a nested case-control study within the  EPIC-IBD study 
Category 
Crohn's disease     Ulcerative colitis    
Cases (n=110) Controls (n=440)   Cases (n=244) Controls (n=976)  
Gender (female %) 80(72.7) 320(72.3)   140(57.4) 565(57.9)  
Age at recruitment, years (mean ± SD) 50.1(10.8) 50.1(10.7)   51.7(10.5) 51.7(10.5)  
        
Age at diagnosis years (mean ± SD) 55.4(11.1) -   57.5(10.3) - 
 
Interval between recruitment & diagnosis (mean ± 
SD)                    5.5(2.9) -   5.8(3.3) -  
        
Education(%)        
      Primary school 22(20.0) 107(24.3)   68(27.8) 253(26.0)  
      Technical/professional school 33(30.0) 96(21.8)   62(25.4) 246(25.2) 
 
      Secondary school 30(27.3) 105(23.9)   52(21.3) 201(21.0)  
Longer education(including university) 25(22.7) 125(28.4)   54(22.1) 245(25.1) 
 
Missing 0(0.0) 7(1.6)   8(3.3) 31(3.2)  
        
Smoking status (n, %)   *    * 
Never smoked 41(37.3) 209(47.5)   65(26.6) 418(42.8)  
Former smoker 28(25.5) 121(27.5)   91(37.3) 281(28.8)  
Current smoker 38(34.6) 107(24.3)   82(33.6) 255(26.1)  
Missing 3(2.7) 3(0.7)   6(2.5) 22(2.3)  
        
        
Daily median intakes (mg/day)(inter quartile range)       
Table
2 
 
Total polyphenols 
1091.6(848.8, 
1517.4) 
1164.8(888.8,1517.
4)   
1226.1(911.3,1598.
5) 
   
1203.0(872.1,1595.
3)  
Flavonoids 474.6(276.6, 770.6) 462.8(293.4,707.8)    512.2(306.6,739.8) 475.5(311.4,762.6)  
Anthocyanidins 25.7(9.9, 53.7) 30.4(13.8, 55.5)   23.7(11.5, 49.7) 24.0(11.5,49.0)  
Flavanols 318.4(192.6, 627.6) 327.8 (192.7, 527.1)   379.3(218.1, 581.1)  338.2(203.7,585.1)  
Flavonols 28.2(15.2, 56.9) 29.9(18.0, 52.7)   30.6(17.0,59.5)  31.5(17.8, 59.1)  
Flavanones 21.8(9.0, 48.9) 24.8(11.3, 51.7)   23.9(10.0,50.4) 26.1(10.5, 59.3)  
Flavones 7.7(5.2, 14.4) 9.5 (6.0, 14.1)   9.5( 5.3,14.5) 8.9(5.1,14.5)  
Isoflavones 0.04(0.01, 0.11) 0.03(0.01, 0.08)   0.03(0.01-0.08) 0.03(0.01,0.08)  
        
Lignans 1.4(1.0, 2.0) 1.4(1.1, 1.9)   1.4(1.1, 2.0) 1.4(1.0,2.0)  
        
Stilbenes  0.3(0.1, 1.3) 0.5(0.1, 2.1)    0.5(0.1-2.1) 0.4( 0.1,2.1)  
     Resveratrol 0.1(0.0, 0.2) 0.1(0.0, 0.2)    0.1(0.0-0.3) 0.1(0.0,0.2)  
        
Phenolic acids 560.9(428.4, 806.9) 573.4(396.1, 815.0)    592.4(388.1,868.8) 571.3(365.0,821.3)  
Hydroxybenzoic acid 23.7( 8.7, 79.0) 26.1(11.1, 65.9)   27.9(8.4, 82.7) 28.6(10.4,79.8)  
Hydroxycinnamic acid 522.0(328.3. 777.4) 529.3(341.1, 770.5)    546.9(340.4,818.4) 518.4(301.0,777.3)  
Hydroxyphenylacetic 0.1(0.0, 0.3) 0.1(0.0, 0.3)   0.1(0.0,0.34) 0.1(0.0,0.3)  
* p<0.05    
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Table 2. Odds ratios (OR)  of developing Crohn's disease  according to quartiles  of polyphenol intakes 
Polyphenols 
  Quartile of Intake  P value 
for trend   Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Total polyphenols Cases(n) 32 30 17 31  
 OR (95%CI)  1.00 0.78(0.41,1.47) 0.38(0.18,0.79)* 0.70(0.33,1.49) 0.17 
       
Flavonoids   Cases(n) 32 23 23 32  
 OR (95%CI)  1.00 0.76(0.41,1.43) 0.72(0.37,1.38) 0.94(0.45,1.97) 0.71 
Anthocyanidins Cases(n) 36 26 20 28  
 OR (95%CI)  1.00 0.80(0.43,1.48) 0.56(0.29,1.11) 0.67(0.33,1.36) 0.18 
Flavanols Cases(n) 28 32 18 32  
 OR (95%CI)  1.00 1.14(0.63,2.05) 0.67(0.34,1.34) 1.11(0.51,2.42) 0.75 
Flavonols Cases(n) 31 26 22 31  
 OR (95%CI)  1.00 0.80(0.42,1.51) 0.68(0.32,1.44) 1.00(0.45,2.22) 0.89 
Flavanones Cases(n) 37 24 23 26  
 OR (95%CI)  1.00 0.64(0.35,1.17) 0.57(0.30,1.10) 0.60(0.32,1.13) 0.11 
Flavones Cases(n) 36 32 12 30  
 OR (95%CI)  1.00 0.88(0.49,1.60) 0.33(0.15,0.69)* 0.61(0.28,1.30) 0.03* 
Isoflavones Cases(n) 22 20 40 28  
 OR (95%CI)  1.00 0.98(0.50,1.92) 2.26(1.13,4.53)* 1.59(0.72,3.49) 0.11 
       
Lignans Cases(n) 36 18 27 29  
 OR (95%CI)  1.00 0.47(0.24,0.93)* 0.71(0.37,1.38) 0.67(0.30,1.48) 0.43 
       
Stilbenes Cases(n) 37 32 25 21  
 OR (95%CI)  1.00 0.91(0.50,1.66) 0.67(0.35,1.28)  0.53(0.26,1.08) 0.05 
Resveratrol Cases(n) 40 20 29 21  
 OR (95%CI)  1.00 0.47(0.25,0.90)* 0.60(0.32,1.11) 0.40(0.20,0.82)* 0.02* 
       
Phenolic acids Cases(n) 24 32 28 26  
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 OR (95%CI)  1.00 1.21(0.65,2.27) 1.11(0.58,2.11) 0.83(0.41,1.69) 0.55 
       
Hydroxybenzoic acid Cases(n) 30 27 24 29  
 OR (95%CI)  1.00 0.82(0.43,1.59) 0.77(0.37,1.59) 0.85(0.37,1.95) 0.66 
Hydroxycinnamic acid Cases(n) 25 32 26 27  
 OR (95%CI)  1.00 1.23(0.67,2.28) 0.95(0.50,1.82) 0.91(0.46,1.79) 0.60 
Hydroxyphenylacetic Cases(n) 24 26 36 24  
 OR (95%CI)  1.00 0.94(0.50,1.78) 1.39(0.76,2.56)  0.77(0.37,1.60) 0.87 
Adjusted for: educational level, smoking and total energy; * p<0.05  
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Table  3. Odds ratios (OR) of developing ulcerative colitis according to quartiles of polyphenols intake    
    Quartile of Intake P value for 
trend     Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Total Polyphenols Cases(n) 54 61 66 63  
 OR (95%CI)  1.00 1.46(0.93,2.31) 1.59(0.97,2.61) 1.52(0.88,2.63) 0.16 
       
Flavonoids Cases(n) 66 43 78 57  
 OR (95%CI)  1.00 0.77(0.49,1.22) 1.43(0.92,2.24) 1.10(0.66,1.86) 0.26 
Anthocyanidins Cases(n) 61 62 53 68  
 OR (95%CI)  1.00 1.15(0.76,1.74) 1.03(0.65,1.62) 1.31(0.82,2.10) 0.36 
Flavanols Cases(n) 60 46 80 58  
 OR (95%CI)  1.00 0.85(0.54,1.35)  1.71(1.09,2.69)* 1.30(0.76,2.20) 0.07 
Flavonols Cases(n) 63 64 53 64  
 OR (95%CI)  1.00 1.10(0.71,1.71) 0.91(0.55,1.50) 1.22(0.73,2.03) 0.63 
Flavanones Cases(n) 66 61 66 51  
 OR (95%CI)  1.00        1.00(0.66,1.52) 1.06(0.70,1.62) 0.79(0.50,1.24) 0.38 
Flavones Cases(n) 62 50 67 65  
 OR (95%CI)  1.00 0.97(0.62,1.51) 1.33(0.85,2.08) 1.37(0.81,2.34) 0.14 
Isoflavones Cases(n) 68 61 61 54  
 OR (95%CI)  1.00 0.91(0.59,1.40) 0.84(0.52,1.37) 0.66(0.37,1.20) 0.19 
       
Lignans Cases(n) 70 56 48 70  
 OR (95%CI)  1.00  0.82(0.54,1.26) 0.72(0.45,1.15) 0.99(0.58,1.70) 0.75 
       
Stilbenes Cases(n) 64 53 64 63  
 OR (95%CI)  1.00 0.96(0.62,1.49) 1.16(0.74,1.82) 1.09(0.68,1.75) 0.57 
       
Resveratrol  64 48 67 65  
  1.00 0.79(0.50,1.24) 1.30(0.82,2.04) 1.26(0.75,2.11) 0.32 
Phenolic acids Cases(n) 55 59 60 70  
 OR (95%CI)  1.00 1.17(0.74,1.85) 1.21(0.76,1.94) 1.33(0.81,2.19) 0.28 
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Hydroxybenzoic acid Cases(n) 73 49 59 63  
 OR (95%CI)  1.00 0.67(0.43,1.04) 0.83(0.53,1.32) 1.00(0.59,1.58) 0.92 
Hydroxycinnamic acid Cases(n) 52 61 56 75  
 OR (95%CI)  1.00 1.31(0.82,2.07) 1.22(0.75,1.97) 1.60(0.98,2.63) 0.10 
Hydroxyphenylacetic Cases(n) 63 57 55 69  
 OR (95%CI)  1.00 1.01(0.66,1.55) 0.93(0.59,1.46) 1.14(0.72,1.82) 0.67 
 adjusted for: educational level, smoking and total energy; * p<0.05 
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Table 4. Odds ratios (OR) of developing Crohn's disease  according to quartiles of polyphenol intake in ever smokers  
Polyphenols 
  Quartile of Intake    
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 
P value 
for trend 
Total polyphenols Cases(n) 20 19 9 18  
 
OR 
(95%CI)  
1.00 0.73(0.29,1.83) 0.28(0.10,0.84)* 0.56(0.20,1.63) 0.13 
       
Flavonoids  total  Cases(n) 22 14 10 20  
 
OR 
(95%CI)  
1.00 0.69(0.28,1.70) 0.50(0.18,1.38) 1.14(0.36,3.55) 0.67 
       
Anthocyanidins Cases(n) 24 13 13 16  
 
OR 
(95%CI)  
1.00 0.65(0.26,1.66) 0.51(0.20,1.28)  0.69(0.24,1.96) 0.30 
Flavanols Cases(n) 20 21 5 20  
 
OR 
(95%CI)  
1.00  1.35(0.57,3.20) 0.21(0.05,0.82)* 1.82(0.51,6.51) 0.66 
Flavonols Cases(n) 20 18 11 17  
 
OR 
(95%CI)  
1.00 1.14(0.46,2.83) 0.89(0.28,2.82) 1.07(0.31,3.65) 0.99 
Flavanones Cases(n) 23 13 12 18  
 
OR 
(95%CI)  
1.00 0.33(0.13,0.82) *  0.37(0.13,1.06) 0.40(0.17,0.97) * 0.07 
Flavones Cases(n) 25 19 5 17  
 
OR 
(95%CI)  
1.00  0.67(0.28,1.59) 0.15(0.04,0.54) * 0.56(0.20,1.58) 0.07 
Isoflavones Cases(n) 11 10 25 20  
 
OR 
(95%CI)  
1.00  0.96(0.32,2.87) 3.69(1.15,11.85) * 2.32(0.66,8.11) 0.12 
       
Lignans Cases(n) 23 14 14 15  
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OR 
(95%CI)  
1.00 0.52(0.21,1.29)  0.38(0.13,1.12)  0.38(0.12,1.19) 
0.06 
       
Stilbenes Cases(n) 21 18 14 13  
 
OR 
(95%CI)  
1.00 1.03(0.43,2.51)  0.66(0.25,1.73)   0.57(0.20,1.64) 0.19 
Resveratrol Cases(n) 25 9 19 13  
 
OR 
(95%CI)  
1.00  0.42(0.16,1.13)  0.72(0.30,1.73)   0.39(0.14,1.07) 
0.14 
       
Phenolic acids Cases(n) 14 22 16 14  
 
OR 
(95%CI)  
1.00  1.14(0.45,2.89)   0.90(0.33,2.49)  0.71(0.26,1.96) 0.37 
       
Hydroxybenzoic acid Cases(n) 17 19 14 16  
 
OR 
(95%CI)  
1.00  1.28(0.49,3.35) 1.32(0.47,3.74) 1.42(0.39,5.15) 0.58 
Hydroxycinnamic acid Cases(n) 14 22 14 16  
 
OR 
(95%CI)  
         1.00 1.71(0.67,4.41)  1.00(0.36,2.79) 1.10(0.40,3.01) 0.71 
Hydroxyphenylacetic Cases(n) 14 16 20 16  
 
OR 
(95%CI)  
         1.00  0.82(0.33,2.04)  1.56(0.64,3.80)  1.01(0.37,2.74) 0.56 
adjusted for educational level and total energy; * p<0.05 
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Table 5. Odds ratios (OR) of developing ulcerative colitis and polyphenol intake in ever smokers   
Polyphenols 
  Quartile of Intake  P value 
for 
trend   Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Total polyphenols Cases(n) 39 38 49 47  
 OR (95%CI)  1.00 1.41(0.76, 2.64) 2.00(1.04,3.85)* 2.04(0.95,4.36) 0.05 
       
Flavonoids  total  Cases(n) 49 33 53 38  
 OR (95%CI)  1.00 0.86(0.48,1.55)  1.41(0.79,2.52) 1.23(0.61,2.47) 0.30 
       
Anthocyanidins Cases(n) 43 44 40 46  
 OR (95%CI)  1:00 1.45(0.83,2.52) 1.37(0.75,2.49) 1.50(0.81,2.78) 0.27 
Flavanols Cases(n) 47 35 52 39  
 OR (95%CI)  1:00 0.89(0.51,1.56) 1.44(0.81,2.57) 1.26(0.64,2.51) 0.26 
Flavonols Cases(n) 49 48 36 40  
 OR (95%CI)  1:00 0.97(0.55,1.74) 0.70(0.36,1.36) 1.06(0.54,2.09) 0.88 
Flavanones Cases(n) 42 46 47 38  
 OR (95%CI)  1:00 1.71(0.97,3.03)  1.33(0.76,2.32) 1.05(0.58,1.91) 0.95 
Flavones Cases(n) 47 31 51 44  
 OR (95%CI)  1:00 0.93(0.52,1.65)  1.55(0.88,2.74)   1.34(0.66,2.72) 0.19 
Isoflavones Cases(n) 47 45 42 39  
 OR (95%CI)  1:00 1.04(0.59,1.80) 0.80(0.43,1.50)  0.55(0.26,1.16) 0.12 
       
Lignans Cases(n) 50 41 36 46  
 OR (95%CI)  1:00 0.96(0.56,1.65)  0.78(0.43,1.42)  1.00(0.48,2.08) 0.74 
       
Stilbenes Cases(n) 44 41 45 43  
 OR (95%CI)  1:00 1.08(0.60,1.94) 1.21(0.65,2.25) 0.98(0.52,1.87) 0.99 
Resveratrol Cases(n)         44 38 46 45  
 OR (95%CI)  1:00 0.92(0.51,1.65) 1.37(0.76,2.47) 1.02(0.54,1.90) 0.69 
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Phenolic acids Cases(n) 31 43 46 53  
 OR (95%CI)  1:00 1.70(0.88,3.29) 2.11(1.06,4.22)*  2.14(1.03,4.46)* 0.05 
       
Hydroxybenzoic acid Cases(n) 56 36 41 40  
 OR (95%CI)  1:00 0.71(0.41,1.23) 0.78(0.43,1.40) 0.85(0.45,1.61) 0.60 
Hydroxycinnamic acid Cases(n) 28 46 44 55  
 OR (95%CI)  1:00  1.85(0.96,3.56) 2.01(0.99,4.07)  2.35(1.13,4.91) * 0.04* 
Hydroxyphenylacetic Cases(n) 48 41 36 48  
 OR (95%CI)  1:00 0.93(0.53,1.63) 0.61(0.33,1.15) 1.01(0.54,1.88) 0.78 
adjusted for educational level and total energy; * p<0.05 
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Supplemental Table 1.Participating Centers and Characteristics of the Cohorts 
Centre and 
country 
Size of 
Cohort 
Nature of cohort No. 
Cases of 
Incident 
CD 
No. 
Cases of 
Incident 
UC 
United Kingdom    
Norfolk 25,639 Population-based cohort of men and women aged 45–74 yr. Recruited between 
1993 and 1997. Cases identified up to June 2004 from follow up questionnaires, 
in-patient admission data and histopathology records. 
11 27 
Oxford 50,070 Members of United Kingdom vegetarian societies and readers of health 
food magazines (78% women), aged 20–80 yr recruited between 1994 and 1999. 
Cases identified up to May 2004 by follow-up questionnaires. 
4 15 
Germany     
Heidelberg 25,540 Population-based cohort of men aged 45–65 yr and women aged 35–65 yr. 
Recruited between 1994 and 1998. Cases identified up to June 2007 from follow-
up questionnaires. 
9 4 
Potsdam 27,548 Population-based cohort, men and women, aged 35–64 yr. Recruited between 
1994 and 1998. Cases identified up to April 2007 from follow-up 
Questionnaires. 
4 13 
Italy     
Florence 13,583 Population-based cohort, men and women, aged 34–64 yr. Recruitment 
Between 1993 and 1998. Cases identified from regional database of IBD up 
to May 2004. 
2 8 
Ragusa 6403 Population-based cohort, men and women, aged 34–65 yr recruited between 
1993 and 1997. Case identified up to end of 2010 from follow-up 
questionnaires, in-patient admission data and histopathology records. 
3 19 
Sweden     
Umeå 25,732 Population-based cohort, men and women, aged 30–60 yr. Recruited between 
1992 and 1996. Cases identified up to February 2007 from regional 
database of IBD. 
10 15 
Malmö 28,098 Population-based cohort, men and women, aged 45–69 yr. Recruited between 
1991 and 1996. Cases identified up to October 2003 from regional 
database of IBD. 
11 21 
     
Denmark     
Aarhus and 
Copenhagen 
57,053 Population-based cohort of men and women aged 50–64 yr. Recruited 
between 1993 and 1997. Cases identified up to July 2007 from national 
database of IBD 
11 40 
     
France     
Regions 
throughout the 
country 
72,996 Women aged 40–65 yr recruited between 1990 and 1993 who are members of a 
health insurance scheme for school teachers and co-workers. Cases identified up 
to April 2008 by follow-up questionnaires. 
21 28 
     
The 
Netherlands 
    
Amsterdam, 
Doetinchem, 
Masstricht, and 
Utrecht 
40092 Men and women, aged 20–70 yr recruited between 1993 and 1997 from the 
general population of 3 cities (Amsterdam, Doetinchem, and Masstricht) 
and also the breast cancer screening program in Utrecht. Cases identified 
up to December 2009 by regional IBD databases 
17 41 
     
Greece 28,572 Population-based cohort of men and women aged 29–76 yr recruited between 
1994 and 1999 from 11 regions throughout Greece. Cases identified up to 
September 2011 from follow-up questionnaires and histopathology records 
7 13 
Total 401,326  110 244 
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Supplemental Table 2. Odds ratios (OR) of Crohn's disease  according to quartiles  of polyphenol intake in non-smokers  
Polyphenols 
  Quartile of Intake  P value for 
trend   Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Total polyphenols Cases(n) 11 11 7 12  
 OR (95%CI)  1:00 0.58(0.15,2.30) 0.21(0.04,1.12) 0.38(0.08,1.95) 0.23 
       
Flavonoids  total  Cases(n) 8 9 12 12  
 OR (95%CI)  1:00 1.11(0.29,4.30)  0.90(0.20,4.03) 1.20(0.21,6.72) 0.94 
           
Anthocyanidins Cases(n) 10 12 7 12  
 OR (95%CI)  1:00 1.18(0.33,4.28)  0.93(0.24,3.65) 1.09(0.24,4.91) 0.98 
Flavanols Cases(n) 7 9 13 12  
 OR (95%CI)  1:00 1.04(0.25,4.36)  1.08(0.24,4.88) 1.19(0.20,7.11) 0.84 
Flavonols Cases(n) 10 7 10 14  
 OR (95%CI)  1:00        0.86(0.21,3.46)  1.07(0.27,4.22) 1.72(0.39,7.61) 0.46 
Flavanones Cases(n) 14 11 10 6  
 OR (95%CI)  1:00  2.07(0.53,8.10)  1.15(0.32,4.08) 0.97(0.30,3.12) 0.80 
Flavones Cases(n) 11 13 7 10  
 OR (95%CI)  1:00 0.97(0.30,3.10) 0.59(0.17,2.10)  0.72(0.19,2.71) 0.47 
Isoflavones Cases(n) 10 10 13 8  
 OR (95%CI)  1:00 1.19(0.37,3.86)  1.83(0.45,7.43) 1.55(0.35,6.79) 0.46 
       
Lignans Cases(n) 13 4 13 11  
 OR (95%CI)  1:00 0.06(0.01,0.39)  0.41(0.13,1.35)  0.25(0.06,1.10) 0.41 
       
Stilbenes Cases(n) 10 12 11 8  
 OR (95%CI)  1:00  1.77(0.50,6.29)  1.27(0.34,4.71)  0.58(0.12,2.78) 0.38 
Resveratrol Cases(n) 13 10 10 8  
 OR (95%CI)  1:00 0.60(0.16,2.19)  0.46(0.11,1.98)   0.32(0.07,1.43) 0.14 
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Phenolic acids Cases(n) 10 9 12 10  
 OR (95%CI)  1:00 1.07(0.30,3.80)  0.85(0.27,2.71)  0.87(0.23,3.30) 0.76 
       
Hydroxybenzoic acid Cases(n) 12 6 10 13  
 OR (95%CI)  1:00  0.15(0.02,0.96)*  0.22(0.03,1.46)  0.38(0.05,2.81) 0.91 
Hydroxycinnamic acid Cases(n) 11 9 12 9  
 OR (95%CI)  1:00  0.76(0.22,2.60)  0.96(0.35,2.65)  0.57(0.15,2.20) 0.56 
Hydroxyphenylacetic Cases(n) 10 9 15 7  
 OR (95%CI)  1:00  0.92(0.25,3.47)   1.55(0.49,4.95) 0.49(0.09,2.54) 0.77 
   adjusted for: educational level and total energy; * p<0.05 
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Supplemental Table 3. Odds ratios (OR) of ulcerative colitis according to quartiles of polyphenol intake in non-smokers  
Polyphenols 
  Quartile of Intake  P value 
for trend   Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Total polyphenols Cases(n) 14 22 15 14  
 OR (95%CI)  1:00  1.79(0.68,4.71)  0.95(0.29,3.07)   0.97(0.30,3.09) 0.56 
       
Flavonoids  total  Cases(n) 15 10 24 16  
 OR (95%CI)  1:00 0.62(0.21,1.86)  1.69(0.60,4.76)  0.91(0.29,2.82) 0.70 
Anthocyanidins Cases(n) 13 18 13 21  
 OR (95%CI)  1:00 0.99(0.37,2.65)  0.72(0.24,2.19) 0.97(0.28,3.31) 0.85 
Flavanols Cases(n) 11 10 28 16  
 OR (95%CI)  1:00 0.97(0.30,3.08) 2.80(0.93,8.47) 1.45(0.40,5.29) 0.22 
Flavonols Cases(n) 12 15 16 22  
 OR (95%CI)  1:00 1.11(0.36,3.44) 1.68(0.55,5.12) 2.42(0.74,7.98) 0.08 
Flavanones Cases(n) 22 14 18 11  
 OR (95%CI)  1:00 0.77(0.30,1.94) 0.85(0.33,2.16) 0.61(0.23,1.65) 0.39 
Flavones Cases(n) 13 18 14 20  
 OR (95%CI)  1:00 1.77(0.55,5.75) 0.82(0.25,2.71) 1.99(0.56,7.13) 0.64 
Isoflavones Cases(n) 18 16 17 14  
 OR (95%CI)  1:00 0.60(0.21,1.76) 0.48(0.12,1.91)  0.17(0.03,1.05) 0.07 
       
Lignans Cases(n) 18 13 11 23  
 OR (95%CI)  1:00 0.44(0.17,1.13) 0.23(0.07,0.71) 0.71(0.26,1.96) 0.58 
       
Stilbenes Cases(n) 17 10 18 20  
 OR (95%CI)  1:00 0.50(0.20,1.30)  0.97(0.36,2.64) 0.82(0.28,2.40) 0.97 
Resveratrol Cases(n) 16 9 20 20  
 OR (95%CI)  1:00 0.59(0.20,1.75) 1.08(0.41,2.88) 0.90(0.31,2.59) 0.97 
       
Phenolic acids Cases(n) 23 14 14 14  
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 OR (95%CI)  1:00 0.55(0.22,1.34) 0.70(0.27,1.80) 0.57(0.21,1.56) 0.35 
       
Hydroxybenzoic acid Cases(n) 15 11 18 21  
 OR (95%CI)  1:00 0.59(0.20,1.79) 1.26(0.40,3.96)  1.87(0.65,5.40) 0.16 
Hydroxycinnamic acid Cases(n) 22 14 12 17  
 OR (95%CI)  1:00 0.63(0.24,1.63) 0.65(0.25,1.69)  0.82(0.33,2.06) 0.65 
Hydroxyphenylacetic Cases(n) 13 14 19 19  
 OR (95%CI)  1:00 0.79(0.29,2.13) 1.30(0.50,3.37) 0.97(0.37,2.55) 0.78 
   adjusted for: educational level and total energy; * p<0.05 
 
 
